Illumina Faces Turmoil: February 2025 Sparks its Worst Performance in Over Two Decades

Illumina Inc., a prominent name in the biotechnology industry, has encountered severe financial headwinds, marking February 2025 as the company's most challenging month in 23 years. As global economic conditions shift, the imposition of tariffs by China and diminishing investment capital have combined to create a perfect storm that has severely impacted Illumina's stock, culminating in a staggering decline of nearly 30%.

Continue reading